Edition:
United States

People: Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

114.46USD
20 Jul 2018
Change (% chg)

$-0.53 (-0.46%)
Prev Close
$114.99
Open
$114.44
Day's High
$115.47
Day's Low
$114.41
Volume
203,904
Avg. Vol
258,271
52-wk High
$116.43
52-wk Low
$90.21

Leiden, Jeffrey 

Dr. Jeffrey M. Leiden, M.D. Ph.D. is Independent Director of the Company. Dr. Leiden has been Chairman, President and CEO of Vertex Pharmaceuticals Incorporated since 2011. He has served as a member of Vertex’s board of directors since 2009. Prior to joining Vertex in 2011, Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm he joined in 2006. From 2000 to 2006, he served as President and Chief Operating Officer and Chief Scientific Officer at Abbott Laboratories, where he had responsibility for managing all aspects of Abbott’s global pharmaceutical business. Previously, Dr. Leiden held several academic and hospital appointments, including as Chief of Cardiology at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School. He has extensive consulting experience in the pharmaceutical and medical device areas. Dr. Leiden served as a director of Abbott Laboratories from 2001 to 2006, Shire Pharmaceuticals plc from 2007 to 2011 and Millennium Pharmaceuticals, Inc. from 2008 to 2009. He is a fellow of the American Academy of Arts and Sciences, and an elected member of the Institute of Medicine of the National Academy of Sciences.

Basic Compensation

Total Annual Compensation, USD 113,000
Restricted Stock Awards, USD 167,965
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 280,965

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stephen Rusckowski

10,348,000

Mark Guinan

3,460,400

James Davis

3,270,240

Michael Prevoznik

2,090,390

Jon Cohen

2,491,990

Everett Cunningham

--
As Of  30 Dec 2017